Insider Transactions in Q1 2022 at Turning Point Therapeutics, Inc. (TPTX)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 09
2022
|
Athena Countouriotis President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
62,400
+36.13%
|
-
|
|
Feb 09
2022
|
Athena Countouriotis President & CEO |
SELL
Open market or private sale
|
Direct |
2,971
-5.84%
|
$106,956
$36.3 P/Share
|
|
Feb 09
2022
|
Mohammad Hirmand EVP and Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
33,983
+34.62%
|
-
|
|
Feb 09
2022
|
Mohammad Hirmand EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
669
-8.91%
|
$24,084
$36.3 P/Share
|
|
Feb 09
2022
|
Annette North EVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
16,283
+36.79%
|
-
|
|
Feb 09
2022
|
Annette North EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
669
-5.41%
|
$24,084
$36.3 P/Share
|
|
Feb 09
2022
|
Andrew John Partridge EVP & Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,283
+29.8%
|
-
|
|
Feb 09
2022
|
Andrew John Partridge EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
221
-0.99%
|
$7,956
$36.3 P/Share
|
|
Feb 09
2022
|
Siegfried Reich EVP & Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,567
+44.36%
|
-
|
|
Feb 09
2022
|
Siegfried Reich EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
397
-10.33%
|
$14,292
$36.3 P/Share
|
|
Feb 09
2022
|
Paolo Tombesi EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,283
+35.27%
|
-
|